or
forgot password

Immune Studies of Peripheral Blood From Patients With Malignant Disease Gastrointestinal Tract


N/A
N/A
N/A
Not Enrolling
Both
Colorectal Cancer

Thank you

Trial Information

Immune Studies of Peripheral Blood From Patients With Malignant Disease Gastrointestinal Tract


OBJECTIVES:

- Quantify T cells specific for tumor peptides (carcinoembryonic antigen and MUC1) from
the peripheral blood of patients with colon cancer.

OUTLINE: This is an open-label study.

Patients undergo blood collection at time of follow-up, surgery, thoracentesis,
paracentesis, or leukapheresis (≤ 5 times per year). Blood is analyzed for tumor peptides
(carcinoembryonic antigen and MUC1), circulating cytokines, and lymphocyte response by
ELISA, ELISPOT, or intracellular flow.

PROJECTED ACCRUAL: A total of 140 patients will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Diagnosis of colon cancer

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- Not specified

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Quantitation of T cells specific for tumor peptides (carcinoembryonic antigen and MUC1)

Outcome Time Frame:

3 months

Safety Issue:

No

Principal Investigator

Michael Demeure, MD

Investigator Role:

Study Chair

Investigator Affiliation:

University of Arizona

Authority:

United States: Food and Drug Administration

Study ID:

04-0331-01

NCT ID:

NCT00900432

Start Date:

July 2004

Completion Date:

December 2008

Related Keywords:

  • Colorectal Cancer
  • recurrent colon cancer
  • stage I colon cancer
  • stage II colon cancer
  • stage III colon cancer
  • stage IV colon cancer
  • Colonic Neoplasms
  • Colorectal Neoplasms
  • Digestive System Diseases
  • Gastrointestinal Diseases

Name

Location
Arizona Cancer Center at University of Arizona Health Sciences Center Tucson, Arizona  85724